Trademark Overview
On Saturday, March 7, 2026, a trademark application was filed for TRIAGEIQ with the United States Patent and Trademark Office. The USPTO has given the TRIAGEIQ trademark a serial number of 99688918. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Saturday, March 7, 2026. This trademark is owned by Daniel Medrano. The TRIAGEIQ trademark is filed in the Computer & Software Products & Electrical & Scientific Products, Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Downloadable software for cognitive and behavioral risk screening in chronic disease management, with particular application in patients with diabetes, metabolic syndrome, cardiovascular disease, hypertension, obesity, and related comorbidities; downloadable AI software for cognitive and behavioral screening delivered via text-based interface, chatbot, electronic health record integration, and automated voice communication; downloadable software for scoring patient cognitive and behavioral assessment responses; downloadable software for generating individualized cognitive care plans based on screening data, including but not limited to patients with chronic disease.
Healthcare consulting in chronic disease management, cognitive assessment, and behavioral health screening with particular application in patients with chronic disease including diabetes, metabolic syndrome, cardiovascular disease, hypertension, obesity, and related comorbidities; providing cognitive and behavioral screening programs for medical clinics serving chronic disease patients; clinical program implementation featuring diagnostic screening for cognitive impairment and behavioral health risk factors associated with chronic disease; medical practice management in preventive diagnostics and cognitive care planning; healthcare services featuring AI-assisted cognitive and behavioral screening delivered via any electronic, digital, or artificial intelligence-enabled interface; consulting for medical providers integrating AI-powered cognitive assessment and behavioral health screening into chronic care management programs as supported by clinical evidence.
Medical diagnostic software and instruments for cognitive and behavioral screening and assessment with particular application in patients with chronic disease including diabetes, metabolic syndrome, cardiovascular disease, hypertension, obesity, and related comorbidities; electronic instruments for identifying cognitive impairment, behavioral health risk factors, and neurological risk factors in patients with chronic disease; AI-powered medical screening instruments for cognitive and behavioral assessment delivered via electronic, digital, voice, and text interfaces; diagnostic instruments utilizing automated AI interaction to evaluate patient cognitive and behavioral performance and establish medical necessity for neuropsychological evaluation in patients with chronic disease; medical instruments for generating cognitive care plan recommendations based on diagnostic screening outcomes as supported by clinical evidence.
Software as a service for cognitive risk screening, behavioral health screening, and patient assessment with particular application in patients with chronic disease including diabetes, metabolic syndrome, cardiovascular disease, hypertension, obesity, and related comorbidities; online non-downloadable software for identifying cognitive deficits and behavioral health indicators to establish medical necessity for neuropsychological evaluation; AI-based software for chronic disease patient management and cognitive and behavioral screening delivered via any electronic, digital, or artificial intelligence-enabled interface; AI voice agent technology for automated cognitive and behavioral risk screening in clinical settings; machine learning software for cognitive impairment identification and behavioral health evaluation in chronic disease patients; AI-powered technology for generating individualized cognitive care plans as supported by clinical evidence.”Approximate character count.
